Axi-cel Demonstrates Durable Responses in Indolent Non-Hodgkin Lymphoma

Transplantation and Cellular Therapy 2022: Results of a study examining CAR T threapy axicabtagene ciloleucel for treatment of relapsed indolent lymphomas.